Therapeutic Potential of 5-HT₆ Antagonist SB399885 in Traumatic Stress Disorder

Abstract

Background: Post-traumatic stress disorder is an anxiety disorder for which current therapies are not effective. The 5-Hydroxytryptamine₆ receptor antagonist SB399885 has been reported to have an anxiolytic effect. Hence, the current investigation was undertaken to evaluate its efficacy in post-traumatic stress disorder.

Methods: Rats were placed in the operant box and given 3 foot shocks at intervals of 1 min. The following day the duration of freezing was recorded. For the enhanced sustained prolonged stress (ESPS), the rats were subjected to various stressors such as restraint stress (2 h), forced swim (20 min), and anesthesia, followed by a foot shock for 4 s. The rats were then subjected to the elevated plus maze.

Results: Treatment with SB399885 (1 and 3 mg/kg, i. p.) was found to significantly decrease the freezing time in the contextual fear conditioning model. Rats subjected to ESPS spent greater time in the open arm of the elevated plus maze when administered SB399885 at the above mentioned doses. The treatment had no effect on locomotor activity. SB399885 decreased the 5-hydroxytryptamine levels in the amygdala at doses that were effective in the above animal models.

Conclusion: 5-Hydroxytryptamine₆ antagonists may hold potential in the treatment of post-traumatic stress.

Key words

elevated plus maze - fear conditioning - 5-HT₆ antagonist

• References

• 1 Stanford SC. Central noradrenergic neurons and stress. Pharmacol Ther 1995; 68: 297-242
• 2 Kozaric-Kovacic D. Psychopharmacotherapy of posttraumatic stress disorder. Croat Med J 2008; 49: 459-475
• 3 Stein DJ, Ipser J, McAnda N. Pharmacotherapy of posttraumatic stress disorder: a review of meta-analyses and treatment guidelines. CNS Spectr 2009; 14: 25-31
• 4 Nash JR, Sargent PA, Rabiner EA et al. Serotonin 5-HT1A receptor binding in people with panic disorder: positron emission tomography study. Br J Psychiatry 2008; 193: 229-234
• 5 Wesołowska A. Potential role of the 5-HT6 receptor in depression and anxiety: an overview of preclinical data. Pharmacol Rep 2010; 62: 564-577
• 6 Hamon M, Doucet E, Lefevre K et al. Antibodies and antisense oligonucleotide for probing the distribution and putative functions of central 5-HT6 receptors. Neuropsychopharmacology 1999; 21: 68-76
• 7 Otano A, Frechilla D, Cobreros A et al. Anxiogenic-like effects and reduced stereological counting of immunolabelled 5-hydroxytryptamine receptors in rat nucleus accumbens by antisense oligonucleotides. Neuroscience 1999; 92: 1001-1009
• 8 Dawson LA. The central role of 5-HT6 receptors in modulating brain neurochemistry. Int Rev Neurobiol 2011; 96: 1-26
• 9 Krishnamurthy S, Garabadu D, Joy KP. Risperidone ameliorates post-traumatic stress disorder-like symptoms in modified stress re-stress model. Neuropharmacology 2013; 75: 62-77
• 10 Cai WH, Blundell J, Han J et al. Postreactivation glucocorticoids impair recall of established fear memory. J Neurosci 2006; 26: 9560-9566
• 11 Wang HN, Peng Y, Tan QR et al. Quetiapine ameliorates anxiety-like behavior and cognitive impairments in stressed rats: implications for the treatment of posttraumatic stress disorder. Physiol Res 2010; 59: 263-271
• 12 Cierpial MA, Shasby DE, Murphy CA et al. Open-field behavior of spontaneously hypertensive and Wistar-Kyoto normotensive rats: effects of reciprocal cross-fostering. Behav Neural Biol 1989; 51: 203-210
• 13 Abraham R, Shanmuganathan D, Saralaya R et al. Differences in the antidepressant like activity of SB399885 on acute and multiple dosing. Society for Neuroscience Meeting 2012; Abstract Program#/Poster# 775.12: /EE14
• 14 Gonzalez LE, Quinone B, Rangel A et al. Tonic and phasic alteration in amygdala 5-HT, glutamate and GABA transmission after prefrontal cortex damage in rats. Brain Res 2004; 1005: 154-163
• 15 Amat J, Matus-Amat P, Watkins LR et al. Escapable and inescapable stress differentially alter extracellular levels of 5-HT in the basolateral amygdala of the rat. Brain Res 1998; 812: 113-120
• 16 Nikiforuk A, Kos T, Wesołowska A. The 5-HT6 receptor agonist EMD 386088 produces antidepressant and anxiolytic effects in rats after intrahippocampal administration. Psychopharmacology (Berl) 2011; 217: 411-418
• 17 Woolley ML, Marsden CA, Fone KC. 5-ht6 receptors. Curr Drug Targets CNS Neurol Disord 2004; 3: 59-79
• 18 Steckler T, Risbrough V. Pharmacological treatment of PTSD – established and new approaches. Neuropharmacology 2012; 62: 617-627
• 19 Morairty SR, Hedley L, Flores J et al. Selective 5HT2A and 5HT6 receptor antagonists promote sleep in rats. Sleep 2008; 31: 34-44